Why are telehealth providers prescribing GLP-1 drugs off-label for addiction?

STAT reported that telehealth providers are promoting GLP-1 drugs for addiction before any FDA approval for that use. Experts warned this model could fragment care and expose patients to unknown risks, raising concerns for regulators, payers, PBMs, and employer benefit managers as demand outpaces clinical consensus.